WO2005102247A3 - Mehrphasenpräparat zur kontrazeption auf der basis eines natürlichen estrogens - Google Patents

Mehrphasenpräparat zur kontrazeption auf der basis eines natürlichen estrogens Download PDF

Info

Publication number
WO2005102247A3
WO2005102247A3 PCT/EP2005/004022 EP2005004022W WO2005102247A3 WO 2005102247 A3 WO2005102247 A3 WO 2005102247A3 EP 2005004022 W EP2005004022 W EP 2005004022W WO 2005102247 A3 WO2005102247 A3 WO 2005102247A3
Authority
WO
WIPO (PCT)
Prior art keywords
natural estrogen
preparation based
preparation
contraceptive preparation
phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/004022
Other languages
English (en)
French (fr)
Other versions
WO2005102247A2 (de
Inventor
Jan Endrikat
Bernd Duesterberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34979546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005102247(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CN2005800125561A priority Critical patent/CN1946383B/zh
Priority to DK05730867.8T priority patent/DK1740163T4/da
Priority to AT05730867T priority patent/ATE473734T1/de
Priority to SI200531115T priority patent/SI1740163T2/sl
Priority to UAA200611799A priority patent/UA83915C2/ru
Priority to BRPI0510005-4A priority patent/BRPI0510005A/pt
Priority to MEP-2010-149A priority patent/ME01183B/de
Priority to EP05730867.8A priority patent/EP1740163B2/de
Priority to RS20100413A priority patent/RS51434B2/sr
Priority to US11/578,771 priority patent/US8071577B2/en
Priority to EA200601844A priority patent/EA010313B1/ru
Priority to CA002561839A priority patent/CA2561839C/en
Priority to PL05730867T priority patent/PL1740163T5/pl
Priority to MXPA06012213A priority patent/MXPA06012213A/es
Priority to AU2005235418A priority patent/AU2005235418C1/en
Priority to HK07107104.1A priority patent/HK1099701B/xx
Priority to NZ550417A priority patent/NZ550417A/en
Application filed by Schering AG filed Critical Schering AG
Priority to ES05730867T priority patent/ES2348038T5/es
Priority to JP2007508800A priority patent/JP4908399B2/ja
Priority to HRP20100513TT priority patent/HRP20100513T4/hr
Priority to DE502005009904T priority patent/DE502005009904D1/de
Publication of WO2005102247A2 publication Critical patent/WO2005102247A2/de
Publication of WO2005102247A3 publication Critical patent/WO2005102247A3/de
Priority to IL178510A priority patent/IL178510A/en
Anticipated expiration legal-status Critical
Priority to NO20065292A priority patent/NO344098B1/no
Priority to ZA2006/09594A priority patent/ZA200609594B/en
Priority to US12/726,799 priority patent/US20100173877A1/en
Priority to US13/020,913 priority patent/US20110124612A1/en
Priority to IL239861A priority patent/IL239861A0/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Die Erfindung betrifft ein Mehrphasenpräparat zur Kontrazeption auf der Ba­sis eines natürlichen Estrogens in Kombination mit einem synthetischen Ge­stagen, welches im Vergleich zu den gattungsgemäßen herkömmlichen ovula­tionshemmenden Präparaten, die sich seit langem in der breiten Anwendung als zuverlässig und sicher erwiesen haben, über die gesamte Dauer des Zyk­lus eine höhere kontrazeptive Sicherheit realisiert, das zyklische Blutungs­verhalten verbessert und Nebenwirkungen minimiert, wie Brustspannen, Kopf­schmerzen, depressive Verstimmungen und Libidoveränderungen u.ä., bzw. ausschließt.
PCT/EP2005/004022 2004-04-20 2005-04-15 Mehrphasenpräparat zur kontrazeption auf der basis eines natürlichen estrogens Ceased WO2005102247A2 (de)

Priority Applications (27)

Application Number Priority Date Filing Date Title
DE502005009904T DE502005009904D1 (de) 2004-04-20 2005-04-15 Mehrphasenpräparat zur kontrazeption auf der basis eines natürlichen estrogens
AU2005235418A AU2005235418C1 (en) 2004-04-20 2005-04-15 Multi-phase contraceptive preparation based on a natural estrogen
AT05730867T ATE473734T1 (de) 2004-04-20 2005-04-15 Mehrphasenpräparat zur kontrazeption auf der basis eines natürlichen estrogens
SI200531115T SI1740163T2 (sl) 2004-04-20 2005-04-15 Večfazni pripravek za kontracepcijo na osnovi naravnega estrogena
UAA200611799A UA83915C2 (ru) 2004-04-20 2005-04-15 Многофазный препарат для контрацепции на основе натурального эстрогена
BRPI0510005-4A BRPI0510005A (pt) 2004-04-20 2005-04-15 preparação contraceptiva multifase baseada em estrogênio natural com um gestagênio sintético
MEP-2010-149A ME01183B (de) 2004-04-20 2005-04-15 Mehrphasenpräparat zur kontrazeption auf der basis eines natürlichen estrogens
EP05730867.8A EP1740163B2 (de) 2004-04-20 2005-04-15 Mehrphasenpräparat zur kontrazeption auf der basis eines natürlichen estrogens
NZ550417A NZ550417A (en) 2004-04-20 2005-04-15 Multi-phase contraceptive preparation based on a natural estrogen
US11/578,771 US8071577B2 (en) 2004-04-20 2005-04-15 Multi-phase contraceptive preparation based on a natural estrogen
EA200601844A EA010313B1 (ru) 2004-04-20 2005-04-15 Многофазный препарат для контрацепции на основе натурального эстрогена
CA002561839A CA2561839C (en) 2004-04-20 2005-04-15 Multi-phase contraceptive preparation based on a natural estrogen
PL05730867T PL1740163T5 (pl) 2004-04-20 2005-04-15 Wielofazowy preparat antykoncepcyjny na bazie naturalnego estrogenu
MXPA06012213A MXPA06012213A (es) 2004-04-20 2005-04-15 Preparado polifasico para la contracepcion a base de un estrogeno natural.
HK07107104.1A HK1099701B (en) 2004-04-20 2005-04-15 Multi-phase contraceptive preparation based on a natural estrogen
CN2005800125561A CN1946383B (zh) 2004-04-20 2005-04-15 基于天然雌激素的多段式避孕制剂
RS20100413A RS51434B2 (sr) 2004-04-20 2005-04-15 Višefazni preparat za kontracepciju na bazi prirodnog estrogena
DK05730867.8T DK1740163T4 (da) 2004-04-20 2005-04-15 Flerfasepræparat til kontraception på basis af et naturligt østrogen
ES05730867T ES2348038T5 (es) 2004-04-20 2005-04-15 Preparado polifásico para la contracepción sobre la base de un estrógeno natural
JP2007508800A JP4908399B2 (ja) 2004-04-20 2005-04-15 天然エストロゲンに基づく段階型避妊製剤
HRP20100513TT HRP20100513T4 (hr) 2004-04-20 2005-04-15 Višefazni kontracepcijski pripravak zasnovan na prirodnom estrogenu
IL178510A IL178510A (en) 2004-04-20 2006-10-05 A multi-phase preparation for the prevention of natural estrogen-based pregnancy
NO20065292A NO344098B1 (no) 2004-04-20 2006-11-17 Multifaseprevensjonsmiddel basert på et naturlig østrogen
ZA2006/09594A ZA200609594B (en) 2004-04-20 2006-11-17 Multi-phase contraceptive preparation based on a estrogen
US12/726,799 US20100173877A1 (en) 2004-04-20 2010-03-18 Multi-phase contraceptive preparation based on a natural estrogen
US13/020,913 US20110124612A1 (en) 2004-04-20 2011-02-04 Multi-phase contraceptive preparation based on a natural estrogen
IL239861A IL239861A0 (en) 2004-04-20 2015-07-09 A multi-phase birth control preparation based on natural estrogen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004019743.1 2004-04-20
DE102004019743A DE102004019743B4 (de) 2004-04-20 2004-04-20 Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/726,799 Continuation US20100173877A1 (en) 2004-04-20 2010-03-18 Multi-phase contraceptive preparation based on a natural estrogen

Publications (2)

Publication Number Publication Date
WO2005102247A2 WO2005102247A2 (de) 2005-11-03
WO2005102247A3 true WO2005102247A3 (de) 2006-01-12

Family

ID=34979546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/004022 Ceased WO2005102247A2 (de) 2004-04-20 2005-04-15 Mehrphasenpräparat zur kontrazeption auf der basis eines natürlichen estrogens

Country Status (37)

Country Link
US (3) US8071577B2 (de)
EP (1) EP1740163B2 (de)
JP (1) JP4908399B2 (de)
KR (1) KR20060134168A (de)
CN (1) CN1946383B (de)
AR (2) AR048830A1 (de)
AT (1) ATE473734T1 (de)
AU (1) AU2005235418C1 (de)
BR (1) BRPI0510005A (de)
CA (1) CA2561839C (de)
CR (1) CR8695A (de)
CY (1) CY1111292T1 (de)
DE (2) DE102004019743B4 (de)
DK (1) DK1740163T4 (de)
EA (1) EA010313B1 (de)
EC (1) ECSP067000A (de)
ES (1) ES2348038T5 (de)
GT (1) GT200500093A (de)
HR (1) HRP20100513T4 (de)
IL (2) IL178510A (de)
ME (1) ME01183B (de)
MX (1) MXPA06012213A (de)
MY (1) MY143669A (de)
NO (1) NO344098B1 (de)
NZ (1) NZ550417A (de)
PA (1) PA8630901A1 (de)
PE (1) PE20060308A1 (de)
PL (1) PL1740163T5 (de)
PT (1) PT1740163E (de)
RS (1) RS51434B2 (de)
SI (1) SI1740163T2 (de)
SV (1) SV2006002090A (de)
TW (1) TWI351960B (de)
UA (1) UA83915C2 (de)
UY (1) UY28863A1 (de)
WO (1) WO2005102247A2 (de)
ZA (1) ZA200609594B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
DK1937274T3 (da) * 2005-10-13 2012-06-18 Bayer Pharma AG Anvendelse af estradiolvalerat i kombination med dienogest til oral behandling af dysfunktionel uterin blødning i enhed med en oral kontraception
SI1787649T1 (sl) * 2005-10-13 2009-08-31 Bayer Schering Pharma Ag Uporaba estradiolvalerata v kombinaciji z dienogestom za oralno terapijo disfunkcionalne maternične krvavitve skupaj z oralno kontracepcijo
US8153616B2 (en) * 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
CA2640520C (en) 2006-03-02 2014-04-22 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method
DE102006010329A1 (de) * 2006-03-06 2007-09-13 Höltge, Michael, Dipl.-Med. Hormonelles Kontrazeptivum auf der Basis eines Estrogens, eines Gestagens oder einer Kombination von Estrogenen und Gestagenen unter der Zugabe von Testosteron
EP1930010A1 (de) * 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
US20090117183A1 (en) * 2007-11-05 2009-05-07 Sabine Fricke Oral contraceptive containing a gestagen and an estrogen combined with pharmaceutically acceptable auxiliary agents and/or excipients, but not containing lactose, and method of making same
WO2012155091A1 (en) * 2011-05-11 2012-11-15 Kirax Corporation Package for improved treatment of conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0770388A1 (de) * 1995-10-28 1997-05-02 JENAPHARM GmbH Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
US6312722B1 (en) * 1995-06-28 2001-11-06 Schering Aktiengesellschaft Pharmaceutical combined preparation, kit and method for hormonal contraception
US6670350B1 (en) * 1999-02-18 2003-12-30 Jenapharm Gmbh & Co. Kg Method of administering dienogest in high dosages to reduce the body of the breast and pharmaceutical composition for same
WO2004112797A1 (en) * 2003-06-25 2004-12-29 Schering Ag Hormone replacement- and depression therapy comprising dienogest

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4168068A (en) 1969-07-22 1971-01-28 Unisearch Limited Improvements in or relating to oral contraceptives
US3639600A (en) 1969-08-28 1972-02-01 Upjohn Co Process of establishing cyclicity in a human female
US3795734A (en) 1970-04-20 1974-03-05 American Home Prod Cyclic regimen of hormone administration for contraception
US4066757A (en) 1973-03-26 1978-01-03 Ortho Pharmaceutical Corporation Oral contraceptive regimen
DE2365103C3 (de) 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen V erwendung von Hormonen zur Kontrazeption
DE2431704A1 (de) 1974-07-02 1976-01-22 Asche Ag Stufenkombinationspraeparate per kontrazeption
DE2645307A1 (de) 1976-10-05 1978-04-06 Schering Ag Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungen
JPS6019734B2 (ja) 1977-05-12 1985-05-17 三共株式会社 安定なプロスタグランジンｅ類製剤の製法
US4272270A (en) 1979-04-04 1981-06-09 Petrochem Consultants, Inc. Cryogenic recovery of liquid hydrocarbons from hydrogen-rich
NL8001593A (nl) * 1980-03-18 1981-10-16 Akzo Nv Meerfasisch combinatiepreparaat voor orale anticonceptie.
US4390531A (en) 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4921843A (en) 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
US4616006A (en) 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4530839A (en) 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4628051A (en) 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3341638A1 (de) 1983-11-17 1984-05-03 Hermann Dr.rer.nat. 8000 München Heßlinger Dreiphasen-praeparat zur empfaengnisverhuetung aus ethinyloestradiol und lynestrenol
DE3347125A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
AU581486B2 (en) 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
DK174724B1 (da) 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
CA2005933A1 (en) 1989-01-09 1990-07-09 Jesse Hipps, Sr. Photohardenable composition containing five member aromatic group with imine moiety
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
DE4104385C1 (de) 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
DE4224534A1 (de) 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Ovulationshemmendes Mittel zur hormonalen Kontrazeption
DE4308406C1 (de) 1993-03-12 1994-06-16 Jenapharm Gmbh Kombinationspräparat zur Kontrazeption
DE4313926A1 (de) * 1993-04-28 1994-11-03 Jenapharm Gmbh Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption
DE4339934C2 (de) 1993-05-07 1995-05-24 Klaus Dr Med Umbreit Ovulationshemmendes Mittel zur hormonalen Kontrazeption
NL9301562A (nl) 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4429374C1 (de) 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
US20050032756A1 (en) 1995-10-28 2005-02-10 Michael Dittgen Multistage preparation for contraception based on natural estrogens
ATE249222T1 (de) 1996-07-26 2003-09-15 Wyeth Corp Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten
KR100518102B1 (ko) 1996-07-26 2005-10-04 와이어쓰 프로게스틴과 에스트로겐의 혼합물을 포함하는 단일상 피임약 키트
SI0917466T1 (en) 1996-07-26 2005-02-28 Wyeth Oral contraceptive
DE19654609A1 (de) 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
US6987101B1 (en) 1996-12-20 2006-01-17 Schering Aktiengesellschaft Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6312772B1 (en) * 1997-10-20 2001-11-06 Hoechst Celanese Corporation Multilayer laminate formed from a substantially stretched non-molten wholly aromatic liquid crystalline polymer and non-polyester thermoplastic polymer
DE10045380A1 (de) 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
US6699820B2 (en) 2001-03-02 2004-03-02 Hartmut Ulrich Bielefeldt Method for making a superconductor with enhanced current carrying capability
IL161105A0 (en) 2001-09-29 2004-08-31 Solvay Pharm Gmbh Estrogen/gestagen combination preparation and application thereof
EP1462106A1 (de) 2003-03-28 2004-09-29 Pantarhei Bioscience B.V. Pharmazeutishe Zusammensetzungen und Kits enthaltend 17-Betaestradiol und Progesteron zur Behandlung von Gynäcologischen Storungen
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
MX2007004120A (es) 2004-10-07 2007-06-15 Duramed Pharmaceuticals Inc Metodos de tratamiento hormonal utilizando regimentes de ciclo prolongado de dosis ascendente.
TW200726473A (en) 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
SI1787649T1 (sl) 2005-10-13 2009-08-31 Bayer Schering Pharma Ag Uporaba estradiolvalerata v kombinaciji z dienogestom za oralno terapijo disfunkcionalne maternične krvavitve skupaj z oralno kontracepcijo
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312722B1 (en) * 1995-06-28 2001-11-06 Schering Aktiengesellschaft Pharmaceutical combined preparation, kit and method for hormonal contraception
EP0770388A1 (de) * 1995-10-28 1997-05-02 JENAPHARM GmbH Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
US6670350B1 (en) * 1999-02-18 2003-12-30 Jenapharm Gmbh & Co. Kg Method of administering dienogest in high dosages to reduce the body of the breast and pharmaceutical composition for same
WO2004112797A1 (en) * 2003-06-25 2004-12-29 Schering Ag Hormone replacement- and depression therapy comprising dienogest

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GRASER T ET AL: "Dienogest as a progestin for hormone replacement therapy", DRUGS OF TODAY 1999 SPAIN, vol. 35, no. SUPPL. C, 1999, pages 115 - 126, XP008054769, ISSN: 0025-7656 *
MOORE C ET AL: "Influence of dienogest on ovulation in young fertile women", CLINICAL DRUG INVESTIGATION, vol. 18, no. 4, October 1999 (1999-10-01), pages 271 - 278, XP008054770, ISSN: 1173-2563 *
OETTEL M ET AL: "THE PRECLINICAL AND CLINICAL PROFILE OF DIENOGEST. A SHORT OVERVIEW", DRUGS OF TODAY / MEDICAMENTOS DE ACTUALIDAD, J.R. PROUS SS.A. INTERNATIONAL PUBLISHERS, ES, vol. 35, 1999, pages 3 - 12, XP000909647, ISSN: 0025-7656 *
STRECKE J ET AL: "UNTERSUCHUNGEN ZUM VERHALTEN DES VAGINALZYTOGRAMMS BEI BEAGLE-HUENDINNEN WAEHREND TOXIKOLOGISCHER LANGZEITUNTERSUCHUNGEN VON GESTAGENEN", ZEITSCHRIFT FUER VERSUCHSTIERKUNDE, GUSTAV FISCHER JENA VERLAG, JENA, DE, vol. 24, no. 3, 1982, pages 117 - 125, XP001022727, ISSN: 0044-3697 *
ZIMMERMANN H ET AL: "Toxicology of dienogest", DRUGS OF TODAY 1999 SPAIN, vol. 35, no. SUPPL. C, 1999, pages 13 - 26, XP008054776, ISSN: 0025-7656 *

Also Published As

Publication number Publication date
NO20065292L (no) 2007-01-17
EP1740163A2 (de) 2007-01-10
DK1740163T3 (da) 2010-10-18
UY28863A1 (es) 2005-11-30
AR048830A1 (es) 2006-05-31
HK1099701A1 (zh) 2007-08-24
RS51434B2 (sr) 2020-11-30
CY1111292T1 (el) 2015-08-05
CN1946383B (zh) 2010-06-09
ES2348038T5 (es) 2020-09-14
EA010313B1 (ru) 2008-08-29
AU2005235418A1 (en) 2005-11-03
AU2005235418C1 (en) 2015-05-21
IL178510A (en) 2015-08-31
PA8630901A1 (es) 2006-05-16
CA2561839A1 (en) 2005-11-03
UA83915C2 (ru) 2008-08-26
US20110124612A1 (en) 2011-05-26
IL178510A0 (en) 2007-02-11
PL1740163T5 (pl) 2020-10-05
SI1740163T1 (sl) 2010-11-30
ES2348038T3 (es) 2010-11-29
BRPI0510005A (pt) 2007-09-18
ECSP067000A (es) 2006-12-29
DE102004019743B4 (de) 2008-11-27
MY143669A (en) 2011-06-30
PT1740163E (pt) 2010-09-28
JP4908399B2 (ja) 2012-04-04
NZ550417A (en) 2010-01-29
SI1740163T2 (sl) 2020-04-30
IL239861A0 (en) 2015-08-31
CA2561839C (en) 2009-09-29
DK1740163T4 (da) 2020-04-06
TW200534860A (en) 2005-11-01
PL1740163T3 (pl) 2010-12-31
NO344098B1 (no) 2019-09-02
CR8695A (es) 2008-07-29
EA200601844A1 (ru) 2007-04-27
RS51434B (sr) 2011-04-30
PE20060308A1 (es) 2006-05-25
AU2005235418B2 (en) 2009-08-06
US20100173877A1 (en) 2010-07-08
AR084229A2 (es) 2013-05-02
US20070259840A1 (en) 2007-11-08
EP1740163B1 (de) 2010-07-14
HRP20100513T4 (hr) 2020-10-02
ATE473734T1 (de) 2010-07-15
CN1946383A (zh) 2007-04-11
WO2005102247A2 (de) 2005-11-03
ME01183B (de) 2013-03-20
GT200500093A (es) 2006-04-17
DE102004019743A1 (de) 2005-11-24
JP2007533681A (ja) 2007-11-22
US8071577B2 (en) 2011-12-06
KR20060134168A (ko) 2006-12-27
ZA200609594B (en) 2008-04-30
DE502005009904D1 (de) 2010-08-26
MXPA06012213A (es) 2007-01-17
EP1740163B2 (de) 2020-01-15
HRP20100513T1 (hr) 2010-11-30
SV2006002090A (es) 2006-02-15
TWI351960B (en) 2011-11-11

Similar Documents

Publication Publication Date Title
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
WO2009088401A3 (en) Immunostimulatory combinations of tlr3 ligands with tlr2 and/or tlr9 agonists and methods of use
WO2012005876A3 (en) Compositions and methods for stimulating magp-1 to improve the appearance of skin
WO2006014930A3 (en) Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
WO2011090821A3 (en) Composite particles, compositions and methods
WO2006026394A3 (en) Method of eliciting an immune response against hiv
WO2011028888A3 (en) Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with an improved immunogenicity
WO2005023185A3 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
WO2005102247A3 (de) Mehrphasenpräparat zur kontrazeption auf der basis eines natürlichen estrogens
PL2167117T3 (pl) Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi
WO2004098517A8 (en) Methods of hormonal treatment utilizing extended cycle contraceptive regimens
WO2013006336A3 (en) Methods and compositions useful for treating fitzpatrick type iv, v or vi skin
UA98638C2 (ru) Композиция для регулирования трофизма волосяных фолликулов и/или продуцирования кожного сала на коже
WO2006071989A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2007082001A3 (en) Extract of r. miehei
ZA200602069B (en) The use of Labiatae herb preparations for foam enhancement of beverages
MY190399A (en) A composition comprising cistanche and ginkgo extracts, the composition useful for improving memory of a subject
WO2006069048A3 (en) Reduction of hair growth
WO2007050405A3 (en) The induction of indoleamine 2,3-dioxygenase in dendritic cells by tlr ligands and uses thereof
WO2012169860A3 (ko) 콩 추출물을 포함하는 탈모 방지 또는 육모 촉진용 조성물
WO2006024240A3 (es) Composición vacunal contra el virus de la hepatitis c.
CA127748S (en) Bakeware
CA98132S (en) Tabletop folder/inserter
EP2465490A3 (de) Zusammensetzungen mit Lilium siberia-Extrakten und Verwendungen dafür
CN202706448U (zh) 新型地板连接件

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2561839

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005235418

Country of ref document: AU

Ref document number: 178510

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 550417

Country of ref document: NZ

Ref document number: 5818/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020067021681

Country of ref document: KR

Ref document number: 12006502079

Country of ref document: PH

Ref document number: 2007508800

Country of ref document: JP

Ref document number: CR2006-008695

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/012213

Country of ref document: MX

Ref document number: 200580012556.1

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005235418

Country of ref document: AU

Date of ref document: 20050415

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005235418

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 06115743

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2006/09594

Country of ref document: ZA

Ref document number: 200609594

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005730867

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200601844

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020067021681

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005730867

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11578771

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0510005

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 11578771

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: P-2010/0413

Country of ref document: RS

WWE Wipo information: entry into national phase

Ref document number: 239861

Country of ref document: IL